


**LIST OF REFERENCES CITED BY APPLICANT**
*(Use several sheets if necessary)*

ATTY. DOCKET NO.

9426-019

APPLICATION NO.

09/392,500

APPLICANT

Taylor et al.

FILING DATE

September 9, 1999

GROUP

1635

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KAC	AA	WO 9839659	09/11/98	PCT				
I	AB	WO 9738136	10/16/97	PCT				
↓	AC	WO 9637234	11/28/96	PCT				
KAC	AD	EP 0448464	09/25/91	Europe				

**OTHER REFERENCES** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

KAC	AE	Castronovo V et al., "Possible role of human natural anti-Gal antibodies in the natural antitumor defense system," J Natl Cancer Inst. 1989 Feb 1;81(3):212-6.						
	AF	Clark JI et al., "Natural killer cell-directed bispecific antibodies", in <u>Bispecific Antibodies</u> , Fanger MW (ed.), RG Landis Co., Austin, pp. 77-88.						
	AG	de Gast GC et al., "Clinical perspectives of bispecific antibodies in cancer," Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):121-3.						
	AH	Desai PR et al., "Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection," J Immunol Methods. 1995 Dec 27;188(2):175-85.						
	AI	Dodds and Sim (eds.), <u>Complement: A Practical Approach</u> , 1997, Oxford University Press.						
	AJ	Edberg JC et al., "Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes," J Immunol. 1988 Dec 15;141(12):4258-65.						
	AK	Gorter A et al., "Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis," Lab Invest. 1996 Jun;74(6):1039-49.						
	AL	Gross DJ et al., "An immunochemical assay for natural IgM antibodies with an affinity to galactose and whose titer is reduced in the sera of cancer patients," Eur J Cancer Clin Oncol. 1988 Mar;24(3):363-7.						
	AM	Hakomori S, "Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism," Cancer Res. 1996 Dec 1;56(23):5309-18.						
	AN	Higuchi et al., "Natural humoral immunity in patients with malignant diseases", J Clin Lab Immunol. 1980; 4:141-143.						
	AO	Irie K et al., "Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells," Science. 1974 Nov 1;186(4162):454-6.						
↓	AP	Jarvis GA et al., "Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer. 1997 Jun 11;71(6):1049-55.						



KAC	AQ	Maenpaa A et al., "Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas, "Am J Pathol. 1996 Apr;148(4):1139-52.
	AR	Makrides SC et al., "Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement, "J Biol Chem. 1992 Dec 5;267(34):24754-61.
	AS	Mehta RL et al., "Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells, "J Immunol. 1986 Mar 1;136(5):1765-71.
	AT	Mollnes TE et al., "Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay, "J Immunol Methods. 1987 Aug 3;101(2):201-7.
	AU	Niculescu F et al., "Persistent complement activation on tumor cells in breast cancer, "Am J Pathol. 1992 May;140(5):1039-43.
	AV	Okada H and Baba T, "Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane, "Nature. 1974 Apr 5;248(448):521-2.
	AW	Petronis JD et al., "Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer, "Clin Nucl Med. 1998 Oct;23(10):672-7.
	AX	Reiter Y et al., "Killing of human tumor cells by antibody C3b conjugates and human complement", Targeted Diagn Ther. 1989;2:119-35.
	AY	Renner C et al., "Tumor therapy by immune recruitment with bispecific antibodies, "Immunol Rev. 1995 Jun;145:179-209.
	AZ	Seegal BC et al., "Immunoglobulins, complement and foreign antigens in human tumor cells, "Int Arch Allergy Appl Immunol. 1976;52(1-4):205-11.
	BA	Segal DM et al., "T-cell targeted cytotoxicity" in <u>Bispecific Antibodies</u> , Fanger MW (ed.), RG Landis Co., Austin, pp. 27-42.
	BB	Springer GF, "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy, "J Mol Med. 1997 Aug;75(8):594-602.
	BC	Springer GF, "T and Tn, general carcinoma autoantigens, "Science. 1984 Jun 15;224(4654):1198-206.
	BD	Taylor RP et al., "Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor, "Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):152-5.
	BE	Taylor RP et al., "Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment", Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3305-9.
	BF	Taylor RP et al., "Quantitative analyses of C3b capture and immune adherence of IgM antibody/dsDNA immune complexes, "J Immunol. 1989 Dec 1;143(11):3626-31.
	BG	Thornton BP et al., "Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells, "Clin Exp Immunol. 1996 Jun;104(3):531-7.
	BH	Tosic L et al., "Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose, "J Immunol Methods. 1989 Jun 21;120(2):241-9.
	BI	Vetvicka V et al., "Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules, "Clin Exp Immunol. 1999 Feb;115(2):229-35.
✓	BJ	Vetvicka V et al., "Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18), "J Immunol. 1997 Jul 15;159(2):599-605.
KAC	BK	Vetvicka V et al., "Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, "J Clin Invest. 1996 Jul 1;98(1):50-61.

<i>KAC</i>	BL	Weisman HF et al., "Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis, "Science. 1990 Jul 13;249(4965):146-51.
EXAMINER	<i>FE8 Karen Q. Canella</i>	DATE CONSIDERED <i>1/28/01</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

